Farxiga (Dapagliflozin) in Adults 65 and Older: What the Evidence Actually Shows

Why Age Matters for SGLT2 Inhibitors Like Dapagliflozin

Dapagliflozin blocks the sodium-glucose cotransporter-2 in the proximal tubule, causing urinary glucose excretion of roughly 60 to 80 g per day at full effect. That mechanism is directly coupled to kidney filtration capacity. Older adults lose approximately 1 mL/min/1.73 m² of GFR per year after age 40, meaning a 70-year-old without overt kidney disease may have a baseline eGFR of 55 to 65 mL/min/1.73 m² [1]. Lower filtration reduces glucosuria and, with it, the HbA1c-lowering effect, but it does not abolish the cardiorenal benefits that make dapagliflozin worth prescribing in this population.

How Renal Aging Shapes Efficacy

A pooled analysis of four Phase III dapagliflozin trials found that the HbA1c reduction from dapagliflozin 10 mg was approximately 0.6% in patients with eGFR 45 to 59 mL/min/1.73 m² compared with 0.9% in those with eGFR ≥90 mL/min/1.73 m² [2]. The 2023 American Diabetes Association Standards of Medical Care acknowledge this attenuation explicitly, noting that glycemic efficacy of SGLT2 inhibitors is "substantially reduced" when eGFR falls below 45 mL/min/1.73 m² [3].

Cardiorenal Benefits Outlast Glucose-Lowering

The renal tubular hemodynamic effects, reduced intraglomerular pressure via natriuresis, lower preload, are largely GFR-independent. This explains why trial subgroups with eGFR as low as 25 mL/min/1.73 m² still showed kidney-protective benefit in DAPA-CKD [4].

Prescribers managing an older patient primarily for heart failure or CKD should not withhold dapagliflozin solely because its glucose contribution is modest. The drug's value shifts from metabolic to cardiorenal as eGFR falls.

Cardiovascular Outcome Data in Geriatric Patients: DECLARE-TIMI 58

DECLARE-TIMI 58 (N=17,160) is the largest dapagliflozin cardiovascular outcomes trial on record. The median follow-up was 4.2 years, and 39% of participants were 65 or older [5]. The trial enrolled patients with type 2 diabetes who had either established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors.

Primary and Secondary Outcomes by Age

In the overall trial, dapagliflozin reduced the composite of hospitalization for heart failure or cardiovascular death by 17% (HR 0.83, 95% CI 0.73 to 0.95) [5]. The pre-specified subgroup analysis by age showed consistent benefit across the ≥65 cohort, with no statistically significant interaction term between age and the primary outcome, meaning the drug did not behave differently enough in older patients to warrant a separate efficacy conclusion [5].

Three-point MACE (MI, stroke, CV death) did not reach significance in the full trial (HR 0.93, 95% CI 0.84 to 1.03), a finding that held in older subgroups as well [5].

Fracture and Amputation Signals

Earlier concern about SGLT2 inhibitors and fracture risk originated from canagliflozin data in CANVAS. DECLARE-TIMI 58 found no significant excess in fracture rates with dapagliflozin at 4.2-year median follow-up, and the FDA label for Farxiga does not carry a fracture warning [6]. Still, older adults already carry baseline fall and fracture risk, so volume depletion-related orthostatic hypotension warrants particular attention during initiation.

Heart Failure Evidence: DAPA-HF and DELIVER

DAPA-HF (HFrEF, LVEF ≤40%)

DAPA-HF (N=4,744) enrolled patients with heart failure with reduced ejection fraction, and 55% of participants had type 2 diabetes [7]. The primary outcome, worsening heart failure or cardiovascular death, was reduced by 26% overall (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) [7].

A pre-specified subgroup analysis stratified at age 65 showed an HR of 0.74 (95% CI 0.61 to 0.90) for patients ≥65, nearly identical to the overall trial estimate [7]. The absolute risk reduction was actually numerically larger in older patients because their baseline event rate was higher, translating to a smaller number needed to treat.

The New England Journal of Medicine publication stated: "The benefits of dapagliflozin were consistent across subgroups, including those defined by... Age." [7]

DELIVER (HFpEF, LVEF >40%)

DELIVER (N=6,263) extended dapagliflozin's indication to heart failure with preserved ejection fraction [8]. The mean age was 71.7 years, making it one of the most geriatric-representative HF trials ever conducted. The primary composite outcome (CV death or worsening HF) was reduced by 18% (HR 0.82, 95% CI 0.73 to 0.92, P<0.001) [8]. Because HFpEF is more prevalent in older women, the DELIVER dataset is especially relevant to the typical geriatric cardiology patient.

Chronic Kidney Disease: DAPA-CKD

DAPA-CKD (N=4,304) enrolled patients with CKD and urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g, with eGFR 25 to 75 mL/min/1.73 m² [4]. Roughly 42% did not have type 2 diabetes, confirming the drug's kidney benefit extends beyond glucose control.

Efficacy Across Age Strata

The primary outcome, sustained 50% eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes, was reduced by 39% overall (HR 0.61, 95% CI 0.51 to 0.73, P<0.001) [4]. Subgroup analyses by age showed consistent hazard ratios above and below 65, with no significant interaction (P for interaction = 0.67) [4]. Older patients in DAPA-CKD had higher absolute event rates, again translating the same relative risk reduction into greater absolute benefit per 100 patient-years treated.

eGFR Dip at Initiation

An acute, reversible 2 to 4 mL/min/1.73 m² eGFR drop commonly occurs in the first 2 to 4 weeks of SGLT2 inhibitor initiation due to reduced intraglomerular pressure [4]. This is not nephrotoxicity. Clinicians should recheck a basic metabolic panel at 4 weeks after starting dapagliflozin in older patients, particularly those on ACE inhibitors, ARBs, or diuretics, because the combination may transiently reduce eGFR further [3].

Safety Profile Specific to Adults 65 and Older

Volume Depletion and Hypotension

Osmotic diuresis from glucosuria produces a modest but real natriuretic and diuretic effect. In older adults, reduced thirst perception, decreased renal concentrating ability, and concurrent loop or thiazide diuretic use compound this risk [9]. DECLARE-TIMI 58 reported volume depletion events in 1.0% of the dapagliflozin group versus 0.7% of placebo over 4.2 years [5]. The absolute numbers are small, but in a frail 78-year-old already on furosemide 40 mg daily, even a modest volume shift may cause a syncopal fall.

Practical steps: check sitting and standing blood pressure at the first follow-up after initiation; consider reducing loop diuretic dose by 25 to 50% if systolic BP is below 110 mmHg before starting dapagliflozin [3].

Genital Mycotic Infections

Sustained glycosuria creates a favorable environment for Candida. The DECLARE-TIMI 58 safety data showed mycotic genital infections in 0.9% of women and 0.5% of men on dapagliflozin versus 0.2% in each sex on placebo [5]. Rates in older adults were numerically lower than in younger counterparts, likely due to lower baseline sexual activity and different local microenvironments, though the relative risk remained elevated.

Diabetic Ketoacidosis

SGLT2 inhibitors carry a small but real risk of euglycemic diabetic ketoacidosis (DKA), which may present with normal or only mildly elevated glucose, a diagnostic pitfall for any clinician but especially dangerous in older patients who may minimize or underreport symptoms [6]. The FDA issued a safety communication in 2015 and updated the class label accordingly [6]. Dapagliflozin should be held 3 days before elective surgery or prolonged fasting periods.

Fournier Gangrene

Rare necrotizing fasciitis of the perineum has been reported across SGLT2 inhibitor class. The FDA identified 12 cases in postmarketing surveillance across the drug class through 2018 [6]. The condition carries a mortality risk above 20%. Patients should be educated to report perineal pain, swelling, or fever immediately.

Urinary Tract Infections

Older women have high baseline UTI rates. The DECLARE-TIMI 58 data showed no significant excess in serious UTIs (urosepsis, pyelonephritis) with dapagliflozin [5], but lower urinary tract symptoms warrant standard evaluation and should not automatically be attributed to the drug.

Pharmacokinetics: Does Age Change How the Drug Behaves?

Dapagliflozin is primarily metabolized by UGT1A9 in the liver to an inactive glucuronide metabolite. Renal excretion of unchanged drug is minimal. A dedicated pharmacokinetic study comparing adults 65 to 80 years old to adults 20 to 45 years old found no clinically meaningful difference in AUC or Cmax [10]. The FDA label states that no dose adjustment is required based on age alone [6].

This is clinically reassuring. The 10 mg once-daily dose is standard across age groups, provided eGFR is adequate for the intended indication.

Protein Binding and Drug Interactions

Dapagliflozin is approximately 91% protein-bound. No significant interactions with common geriatric polypharmacy drugs (warfarin, metformin, simvastatin, valsartan, digoxin) have been documented in formal interaction studies [6]. Rifampin reduces dapagliflozin AUC by 22% via UGT1A9 induction, a minor effect unlikely to require dose adjustment in most clinical scenarios.

Dosing and Monitoring Framework for the 65-Plus Patient

The following stepwise approach applies to initiating dapagliflozin in an adult aged 65 or older:

Before prescribing:

• Confirm eGFR within 3 months. Use dapagliflozin for T2D glucose lowering only if eGFR ≥45 mL/min/1.73 m²; use for HF or CKD indications if eGFR ≥25 mL/min/1.73 m² [3][6].
• Obtain a baseline urine albumin-to-creatinine ratio in patients with CKD or hypertension.
• Review diuretic regimen. If the patient is on ≥80 mg furosemide daily, consult with cardiology before adding dapagliflozin.
• Assess fall risk. Patients with a documented history of falls in the prior 12 months warrant orthostatic BP measurement at every visit during the first 3 months.

At initiation:

• Start dapagliflozin 10 mg orally once daily in the morning, with or without food [6].
• Counsel on genital hygiene and recognition of DKA symptoms.
• Hold dapagliflozin if the patient is nil-by-mouth for more than 12 hours (surgical preparation, acute illness with poor oral intake).

Follow-up at 4 weeks:

• Recheck basic metabolic panel (potassium, creatinine, eGFR).
• Repeat orthostatic BP if the patient reported dizziness.
• A 2 to 4 mL/min/1.73 m² acute eGFR decline is expected and does not require discontinuation [4].

Ongoing:

• Monitor eGFR and electrolytes every 3 to 6 months.
• Reassess HbA1c at 3 months if prescribed for glycemic control; expect modest lowering (0.5 to 0.7%) given typical geriatric eGFR range.
• Annual skin and genital inspection is reasonable given the low but persistent mycotic infection risk.

Frailty, Polypharmacy, and Deprescribing Considerations

Adults 65 and older carry an average of 5.8 chronic medications [9]. SGLT2 inhibitors interact minimally at the pharmacokinetic level, but pharmacodynamic overlaps with diuretics, antihypertensives, and insulin deserve attention.

Insulin and Sulfonylurea Co-prescription

Dapagliflozin adds osmotic diuresis on top of any insulin-mediated volume effects. Concurrent sulfonylureas increase hypoglycemia risk independently. The 2023 ADA Standards recommend reducing sulfonylurea or insulin doses when initiating SGLT2 inhibitors if HbA1c is near target [3]. A reasonable starting point: reduce basal insulin by 10 to 20% if fasting glucose is consistently below 130 mg/dL [3].

When to Consider Deprescribing

Deprescribing dapagliflozin is appropriate when eGFR falls below 25 mL/min/1.73 m² and the indication is T2D glucose lowering, when the patient develops recurrent DKA, or when frailty progression makes volume-related adverse events unacceptable [3]. Patients in hospice or with life expectancy under 1 year receive no meaningful benefit from a drug whose cardiovascular outcomes advantages accrue over 2 to 4 years of treatment [11].

What Current Guidelines Say About Geriatric SGLT2 Inhibitor Use

The 2023 ADA Standards of Medical Care in Diabetes designate SGLT2 inhibitors as preferred second-line agents for patients with type 2 diabetes and established ASCVD, heart failure, or CKD, with no age ceiling on this recommendation [3]. The 2022 AHA/ACC Heart Failure Guideline gives dapagliflozin a Class I, Level A recommendation for HFrEF regardless of diabetes status, and again without an upper age limit [12].

The ADA Standards state directly: "For patients with type 2 diabetes and CKD, use of an SGLT2 inhibitor with demonstrated kidney benefit is recommended to reduce the risk of CKD progression and cardiovascular events." [3]

The 2022 KDIGO Diabetes Management in CKD Guideline similarly gives a Grade 1A (strongest) recommendation to SGLT2 inhibitors for patients with T2D and CKD meeting eGFR thresholds, calling it a "cornerstone" of therapy [13].

Neither guideline carves out an exception based solely on age, though both acknowledge that individual clinical judgment is needed for frail patients with multiple comorbidities.

Trial Representation: Are Geriatric Patients Adequately Studied?

A recurring criticism of cardiovascular outcome trials is that they enroll too few patients over 75. In DAPA-HF, 23% of participants were 75 or older [7]. In DELIVER, 24% were 75 or older, and the mean age of 71.7 years is higher than most comparable trials [8]. DAPA-CKD included patients up to age 80+ in its enrollment, with a median age of 62 [4].

Patients over 85 remain underrepresented across all three trials. For this sub-group, the fastest-growing segment of the geriatric population, clinicians must extrapolate from data obtained in slightly younger cohorts, while applying heightened caution around volume status and fall risk.